A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
06/2004
06/30/2004	EP1433462A1 Make-up compositions for dark skin types
06/30/2004	EP1433460A1 Make-up cosmetic composition for dark skin
06/30/2004	EP1237530B1 Hair bleaching and colouring compositions having a ph greater than ph 10 and comprising cholesterol
06/30/2004	EP1082299B1 C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
06/30/2004	EP0958289B1 Amino acid ester containing azole antifungals
06/30/2004	CN1509288A The citrate salt of 5,8,14-triazatetracyclo (10.3.1.0.2,11.0.4,9)-hexadeca-2.(11),3,5,7,9-pentaene
06/30/2004	CN1509174A Tartrate salt of 5,8,14-triazatetracyclo [10,3,1,02,11.04,9]-hexzdeca-2(11),3,5,7,9-pentaene
06/30/2004	CN1155378C Antitumour synergistic composition
06/30/2004	CN1155364C Antiperspirant or deodorant compsns.
06/29/2004	US6756401 Drug mixtures comprising estrogen agonists or antagonists and anticholesterol statins, administered to promote bone formation, prevent bone disorders and/or as anticholesterol agents
06/29/2004	US6756377 Compounds and their use
06/29/2004	US6756045 Topically applied idebenone-containing agent with protective and regenerative effect
06/29/2004	CA2205384C Dihydropyrimidines and uses thereof
06/29/2004	CA2131285C Pharmaceutical inhalation compositions
06/24/2004	WO2004052384A1 Antiviral, anti-infectious and cicatrising properties of extracts of dichrostachys glomerata
06/24/2004	WO2004052314A2 Antimicrobial suture coating
06/24/2004	WO2004052313A2 Anti-infectives
06/24/2004	WO2004052307A2 Encapsulated material released to generate perceivable sensorial indicia
06/24/2004	WO2004052305A2 Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
06/24/2004	WO2004052303A2 A method for creating nuclear receptor activity modulating pharmaceuticals
06/24/2004	WO2004052302A2 A method for creating specific, high affinity nuclear receptor pharmaceuticals
06/24/2004	WO2004052299A2 MODIFICATION OF CYCLOOXYGENASE AND LIPOXYGENASE ACTIVITY WITH ASTERIDAE EXTRACTS AND OPTIONALLy BOSWELLIC ACID
06/24/2004	WO2004052297A2 TREATMENT OF HSV-RELATED PATHOLOGIES USING ssDNA
06/24/2004	WO2004052293A2 Recombinant vaccine against flavivirus infection
06/24/2004	WO2004052285A2 Fat regulation
06/24/2004	WO2004052281A2 Oral lactoferrin in the treatment of sepsis
06/24/2004	WO2004052280A2 Anti-angiogenic compounds and their use in cancer treatment
06/24/2004	WO2004052278A2 Escape mutants of newcastle disease virus as marker vaccines
06/24/2004	WO2004052277A2 Anthrax antitoxins
06/24/2004	WO2004052274A2 Production of bacteriophage compositions for use in phage therapy
06/24/2004	WO2004039320A3 STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
06/24/2004	WO2004037206A3 Methods for diagnosing and treating pre-term labor
06/24/2004	WO2004026224A3 Process for preparing prostaglandin derivatives and starting materials for the same
06/24/2004	WO2004021993A3 Modified asialo-interferons and uses thereof
06/24/2004	WO2004017922A3 Keto cannabinoids with therapeutic indications
06/24/2004	WO2004016227A3 Screening methods for cognitive enhancers
06/24/2004	WO2004010953A3 Implantable artificial organ devices
06/24/2004	WO2003047589A8 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/24/2004	US20040122104 has an enteric coating that delays the release of milnacipran within the stomach, thereby avoiding side effects such as nausea, vomiting, bleeding due to irritation of the gastric mucosa, sleep disturbance, headache etc
06/24/2004	US20040122055 C10 carbonate taxane compositions
06/24/2004	US20040122015 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents
06/24/2004	US20040122005 Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
06/24/2004	US20040121979 Pharmaceutically active uridine esters
06/24/2004	US20040121370 Novel composition and methods for the treatment of immune related diseases
06/24/2004	US20040121010 once-a-day oral milnacipran pulsatile release when administered orally, releases drug in spaced apart "pulses", this delivery profile reduces gastrointestinal side effects by minimizing exposure of the internal mucosal surfaces to the drug
06/24/2004	US20040121009 Method of modifying the release profile of sustained release compositions
06/24/2004	US20040120989 Article for debridement and detoxification of wounds
06/24/2004	US20040120984 Compositions comprising dietary fat complexer and methods for their use
06/24/2004	US20040120968 Methods for regulating bud-hypha transitions and cAMP levels in Candida albicans
06/24/2004	US20040120964 Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
06/24/2004	US20040120958 Modified antibodies to prostate-specific membrane antigen and uses thereof
06/24/2004	US20040120909 Cosmetic method and composition for enhancing attractiveness
06/24/2004	US20040120900 Intraoral calculus dissolving gel composition
06/24/2004	CA2547533A1 Encapsulated material released to generate perceivable sensorial indiciaof discrete event occurence
06/24/2004	CA2526901A1 Antiviral, anti-infectious and cicatrising properties of extracts of dichrostachys glomerata
06/24/2004	CA2508912A1 Oral lactoferrin in the treatment of sepsis
06/24/2004	CA2508830A1 Antimicrobial suture coating
06/24/2004	CA2508766A1 Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid
06/24/2004	CA2508204A1 Treatment of hsv-related pathologies using ssdna
06/23/2004	EP1430054A2 Purification and crystalline forms of zaleplon
06/23/2004	EP1429807A2 Combination of a nsaid and a pde-4 inhibitor
06/23/2004	EP1429800A2 Vaccine and method for treatment of motor neurone diseases
06/23/2004	EP1429760A1 Novel combination
06/23/2004	EP1429754A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
06/23/2004	EP1071427B1 Intermittent claudication therapeutic drugs comprising pyrroloazepines
06/23/2004	EP0969795B1 Oxidising composition and uses for dyeing, permanently setting or bleaching keratin fibres
06/23/2004	CN1506039A Cosmetic method and composition for enhancing attraction
06/23/2004	CN1154725C Human bikunin
06/23/2004	CN1154497C Method of treatment of lever tumours and pharmaceutical compositions for use therein
06/23/2004	CN1154478C Method for producing agglomerates comprising core-shell structure
06/23/2004	CN1154470C High moisture toothpaste composition
06/23/2004	CN1154467C Hair conditioner and 2-in-1 conditioning shampoo
06/22/2004	US6753446 Synthesis of labeled oxalic acid derivatives
06/22/2004	US6753331 Heterocyclic derivatives which inhibit factor Xa
06/22/2004	US6753013 Vitamin d or vitamin d analogue; a corticosteroid; solvent; topical
06/17/2004	WO2004050897A2 Methods for preparing antigen masked red blood cells having reduced hemolysis by sera
06/17/2004	WO2004050848A2 Methods for antigen masking of red blood cells resulting in reduced hemolysis
06/17/2004	WO2004050039A2 Spirocyclic ureas, compositions containing such compounds and methods of use
06/17/2004	WO2004050034A2 Prolonged suppression of electrical activity in excitable tissues
06/17/2004	WO2004050029A2 Novel activated polyethylene glycol compounds
06/17/2004	WO2004050027A2 Materials and methods for treating ocular-related disorders
06/17/2004	WO2004050026A2 Compositions and methods for treating prostate cancer
06/17/2004	WO2004050019A2 Method and compositions for treating anxiety
06/17/2004	WO2004050018A2 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents
06/17/2004	WO2004050015A2 Withania somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof
06/17/2004	WO2004050013A2 Material compositions and related systems and methods for treating cardiac conditions
06/17/2004	WO2004050010A2 Composition, especially a cosmetic composition, containing at least one alkyl para-hydroxybenzoate and at least one lipophilic amino acid derivative
06/17/2004	WO2004049914A2 Methods for reacting an antigen masking compound with red blood cells with high efficiency
06/17/2004	WO2004034999A3 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
06/17/2004	WO2004028460A3 Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
06/17/2004	WO2004017907A3 Blood clot-targeted nanoparticles
06/17/2004	WO2003032810A3 Treatment and diagnosis of insulin resistant states
06/17/2004	US20040116945 Components, systems and methods for forming anastomoses using magnetism or other coupling means
06/17/2004	US20040116496 Asymmetric Disulfides and methods of using same
06/17/2004	US20040116467 Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
06/17/2004	US20040116462 Antiinflammatory agents
06/17/2004	US20040116427 Compounds for inhibition of HIV infection by blocking HIV entry
06/17/2004	US20040116360 Dissolving a polyene antibiotic and a poly(ethylene glycol)-phospholipid in a solvent to produce a solution; evaporating the solvent; adding water to the drug-polymer film and mixing vigorously, whereby micelles are formed
06/17/2004	US20040115652 Antisense oligonucleotides for controlling expression of receptor tyrosine kinase gene and treatment of hyperproliferative disorders; gene expression inhibition
06/17/2004	US20040115206 by contacting with an anti-L1CAM antibody or L1CAM-binding fragment thereof to inhibit cell growth or induce cell death

1 ... 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 ... 295